Organon & Co. $OGN Stock Holdings Raised by Profund Advisors LLC

Profund Advisors LLC grew its position in Organon & Co. (NYSE:OGN) by 360.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 119,069 shares of the company’s stock after acquiring an additional 93,228 shares during the quarter. Profund Advisors LLC’s holdings in Organon & Co. were worth $1,631,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Allied Private Wealth LLC purchased a new position in shares of Organon & Co. during the second quarter worth approximately $33,000. Nykredit A S purchased a new stake in Organon & Co. in the 2nd quarter valued at $76,000. GAMMA Investing LLC raised its position in Organon & Co. by 69.8% in the 2nd quarter. GAMMA Investing LLC now owns 5,782 shares of the company’s stock valued at $78,000 after purchasing an additional 2,376 shares during the last quarter. Wedmont Private Capital purchased a new stake in Organon & Co. in the 2nd quarter valued at $136,000. Finally, WNY Asset Management LLC acquired a new stake in Organon & Co. during the 1st quarter worth $64,000. 77.43% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Five investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and a consensus target price of $11.40.

Organon & Co. Stock Performance

NYSE OGN opened at $13.82 on Tuesday. The company has a quick ratio of 1.44, a current ratio of 1.95 and a debt-to-equity ratio of 8.43. Organon & Co. has a 52-week low of $5.69 and a 52-week high of $13.85. The business’s 50-day moving average price is $13.74 and its 200 day moving average price is $11.50. The firm has a market cap of $3.63 billion, a P/E ratio of 18.19, a P/E/G ratio of 1.28 and a beta of 1.55.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Friday, October 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.06. The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.58 billion. Organon & Co. had a return on equity of 88.97% and a net margin of 3.41%. On average, equities research analysts expect that Organon & Co. will post 3.24 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Monday, November 9th will be paid a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Monday, November 9th. Organon & Co.’s dividend payout ratio (DPR) is 10.53%.

Organon & Co. Profile

Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.